Clinical Trial: Magnesium in Liver Cirrhosis

Study Status: Recruiting
Recruit Status: Unknown status
Study Type: Interventional

Official Title: Magnesium Deficiency in Cirrhotic Patients

Brief Summary:

Several studies have shown in patients magnesium deficiency with liver cirrhosis.

Patients with liver cirrhosis showed considerably reduced muscle strength and muscle magnesium.

We suggest addition of magnesium to patients with established cirrhosis in order to reduce the neuromuscular and neuropsychiatric manifestations of chronic liver disease.

Detailed Summary:

Magnesium is the fourth most abundant cation in the body and plays an important physiological role in many of its functions.

There are no readily available and easy methods to assess magnesium status but it is estimated that magnesium deficiency is a common problem.

Magnesium deficiency can cause a wide variety of features including hypocalcaemia, hypokalaemia and cardiac and neurological manifestations. Chronic low magnesium state has been associated with a number of chronic diseases including diabetes, hypertension, coronary heart disease, and osteoporosis.

There are not enough studies on magnesium status in chronic cirrhotics who may be in depletion. However , several studies have shown in patients magnesium deficiency with liver cirrhosis. Patients with liver cirrhosis showed considerably reduced muscle strength and muscle Mg . Magnesium may have a role in the neuromuscular and neuropsychiatric manifestations of chronic liver disease (hepatic encephalopathy and muscle cramps).

The use of magnesium as a therapeutic agent in asthma, myocardial infarction, and pre-eclampsia is also discussed. We suggest addition of magnesium to patients with established cirrhosis in order to reduce the neuromuscular and neuropsychiatric manifestations of chronic liver disease.

Sponsor: Meir Medical Center

Current Primary Outcome: change in minimal hepatic encephalopathy [ Time Frame: 6 weeks ]

Original Primary Outcome: Same as current

Current Secondary Outcome: change in muscle weakness [ Time Frame: 6 weeks after intervention ]

Original Secondary Outcome: Same as current

Information By: Meir Medical Center

Dates:
Date Received: July 4, 2013
Date Started: August 2013
Date Completion:
Last Updated: July 11, 2013
Last Verified: June 2013